EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Clinical Behaviour and Outcome of Pelvic Osteosarcoma in Dogs: A Retrospective Multicentre Analysis of 74 Cases (2007–2025)

Csilla Fejös, Felicitas Czichon, Maureen Griffin, Natalie Grillo, Quentin Fournier, Michelle L. Oblak, Mikaela Eng‐Toogood, Michael Kent, Isabelle Desmas‐Bazelle, Miriam Kleiter, Laura Marconato, Katie McNaught, Simona Vincenti, Carmit Chalfon, Petros Odatzoglou, Carla Rohrer Bley

Veterinary and Comparative Oncology · 2026-12 · 24 (4) · 819-829

DOI: 10.1111/vco.70106 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Although osteosarcoma is the most common primary bone tumour in dogs, involvement of the pelvic bones is rare. The aim of the present study was to describe clinical presentation, identify possible prognostic factors, and evaluate outcomes in dogs diagnosed with pelvic osteosarcoma. Seventy‐four dogs with cytologically or histologically diagnosed pelvic osteosarcoma were included in this multicentre retrospective study (2007–2025). The median progression‐free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, with comparisons performed using log‐rank tests. Prognostic factors for PFS and OS were assessed using multivariable Cox proportional hazards regression analysis. Lameness (84%) was the most common presenting clinical sign, and the ilium (57%) was the most frequent intrapelvic tumour location. Thirty‐one percent of dogs had metastases at diagnosis, primarily affecting the lungs. The median PFS was 75 days, and the median OS was 79 days. Dogs receiving any treatment had significantly longer PFS (116 vs. 7 days, p < 0.001) and OS (145 vs. 8 days, p < 0.001) than untreated dogs. No factors were significantly associated with PFS. In contrast, dogs with higher body weight and shorter time to diagnosis tended to have more favourable survival, whereas chemotherapy and local progression were associated with poorer outcomes. Despite the overall poor prognosis associated with pelvic osteosarcoma, treatment may extend survival. An individualized, often multimodal approach may provide clinical benefit in selected dogs.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →